4/A: Xilio Therapeutics CEO Amends SEC Filing to Include Power of Attorney for Compliance
Insider Ownership Amendment
Xilio Therapeutics, Inc.'s President and CEO, Rene Russo, filed an amended Form 4 to include a previously omitted power of attorney related to Section 16 reporting obligations.
Summary
- The filing is an amendment (Form 4/A) to a previously filed Form 4 by Rene Russo, President and CEO, Director, and 10% owner of Xilio Therapeutics, Inc.
- The sole purpose of this amendment is to include a Limited Power of Attorney (Exhibit 24.1) that was inadvertently omitted from the original Form 4 filed on January 3, 2025.
- The original Form 4 reported Rene Russo's direct beneficial ownership of 244,883 shares of Xilio Therapeutics Common Stock.
- The Power of Attorney, executed on June 12, 2024, authorizes Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott to execute and file Section 16 forms (Forms 3, 4, and 5) on behalf of Rene Russo.
Sentiment
Score: 5
Explanation: The filing is a neutral, procedural amendment to correct an administrative oversight, with no impact on company operations or financial performance.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Power of Attorney | A Limited Power of Attorney was executed by Rene Russo, authorizing specific individuals to handle Section 16 reporting obligations (Forms 3, 4, and 5) on his behalf. | June 12, 2024 | Enhances compliance efficiency for insider trading reporting requirements. |
Stakeholder Impact
- Shareholders: Provides clarity and ensures compliance regarding insider beneficial ownership reporting.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date the Limited Power of Attorney was executed by Ren Russo. |
| 01/01/2025 | Date of earliest transaction reported in the original Form 4. |
| 01/03/2025 | Date the original Form 4 was filed. |
| 06/18/2025 | Date of signature for the amended Form 4/A filing. |
Keywords
Xilio Therapeutics, XLO, Rene Russo, SEC filing, Form 4, Form 4/A, beneficial ownership, power of attorney, Section 16, insider reporting, corporate governance, compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.